PharmAthene snares two vaccines in buyout

Annapolis, MD-based PharmAthene has agreed to fork over up to $40 million to acquire the vaccines unit of the UK's Avecia Biologics. The acquisition--which is being paid for with a mix of cash and milestone paydays--gives PharmAthene two mid-stage vaccines: an anthrax vaccine that has been tested in two Phase II trials and a plague vaccine that is scheduled to enter Phase II. Avecia gets $10 million up front, $10 million more in a year and $20 million in contract milestones.

''There is a tremendous unmet need for a second-generation anthrax vaccine,'' said PharmAthene CEO David Wright. We believe that Avecia's vaccine is uniquely position to meet the current government requirements."

- here's the release
- read the report from the Gazette

Related Articles:
PharmAthene to go public through merger. Report
Siga Technologies, PharmAthene to merge. Report
EMEA panel recommends goat-milk therapy. Report
PharmAthene finds backers for research pact. Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.